Assessing the Value of Biosimilars: A Cost-Effectiveness Approach for Managed Care Organizations
Published online on November 03, 2025
Abstract
Journal of Pharmacy Practice, Ahead of Print.
Biologic medications are essential for treating chronic diseases but come with high costs, prompting interest in biosimilars as more affordable alternatives. Biosimilars are highly similar to FDA-approved biologics in terms of safety and efficacy, though ...
Biologic medications are essential for treating chronic diseases but come with high costs, prompting interest in biosimilars as more affordable alternatives. Biosimilars are highly similar to FDA-approved biologics in terms of safety and efficacy, though ...